elritercept (KER-050)

Unmet needs include standardized endpoints, biologically stratified trials, and validation of hemoglobin and transfusion responses as markers. Strategies like momelotinib plus luspatercept, earlier intervention, and new molecular therapies could turn treatment from palliation to durable control and disease modification.

P3, N=225, Recruiting, Takeda | N=82 --> 225

P3, N=300, Recruiting, Takeda | N=84 --> 300

P3, N=51, Recruiting, Takeda

P2/3, N=16, Not yet recruiting, Takeda Development Center Americas Inc.

P3, N=300, Recruiting, Takeda | Not yet recruiting --> Recruiting

P3, N=300, Not yet recruiting, Takeda

P2, N=27, Not yet recruiting, Takeda

P2, N=160, Recruiting, Takeda | Trial completion date: Oct 2030 --> Oct 2031

P2, N=135, Recruiting, Takeda | Trial completion date: Jan 2029 --> Feb 2030 | Trial primary completion date: Dec 2026 --> Feb 2028

P2, N=140, Recruiting, Takeda | Trial completion date: Nov 2025 --> Oct 2030 | Trial primary completion date: Jun 2025 --> Oct 2029

The pathobiology of anemia is multifactorial, including progressive bone marrow fibrosis, decreased erythropoiesis due to high hepcidin levels leading to iron sequestration in the reticuloendothelial system, hypersplenism, erythropoiesis inhibition by myelosuppressive JAK inhibitors (ruxolitinib, fedratinib), and others...Conventional agents to manage anemia include erythropoiesis-stimulating agents, danazol, corticosteroids, and immunomodulatory agents, but responses are infrequent and lack durability...Momelotinib and pacritinib (ACVR1/JAK2 inhibitor) are the preferred JAK inhibitors for patients with cytopenias (anemia, thrombocytopenia). Luspatercept and elritercept are activin receptor ligand traps, promoting erythroid maturation and late-stage erythropoiesis...DISC-0974 is a first-in-class anti-hemojuvelin (positive hepcidin regulator) monoclonal antibody that decreased hepcidin expression, increased serum iron, and enhanced erythropoiesis in anemic patients with MF in a phase 1b/2 study. Burgeoning studies of novel anemia-targeted agents and combinations are significantly improving the quality of life and outcomes of patients with MF. The recent approval of momelotinib to treat MF with anemia and the emerging novel anemia-directed strategies in early and advanced clinical development have ushered in a new era in the treatment of MF-related anemia.